Eisai SA
12.6 FTEThe score of Eisai shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Equity +31 % Total assets -13 % Headcount (avg FTE) -1 %
Accounts of the company itself (not consolidated).
The full file covers 11 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Eisai's annual accounts
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | €7.59m | ||||
| Net result | 215,691 € | ||||
| Equity | €4.61m | ||||
| Cash | 117,497 € | ||||
| EBITDA | 308,009 € | ||||
| Total assets | €7.09m |
Filed annual accounts
- Year ended 31 Mar 2026filed on 14 Sep 2026
- Year ended 31 Mar 2025filed on 12 Sep 2025
- Year ended 31 Mar 2024filed on 23 Sep 2024
- Year ended 31 Mar 2023filed on 26 Sep 2023
- Year ended 31 Mar 2022filed on 21 Sep 2022
Eisai's financial analysis
- Solvency65.1%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Eisai
Eisai's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0891.958.055
- VAT number
- BE0891958055
- Peppol
- Registered · 0208:0891958055 · as of 05 Nov 2026
- Legal form
- SA
- Incorporated
- 10 Sep 2007
- Registered office
- 3000 Leuven
- Size
- Small · 12.6 FTE
- Latest accounts
- 2026 · filed on 14 Sep 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Eisai (SA) has been based in Leuven since 2007, active in: wholesale of pharmaceutical and medical goods. For 2026, it reports revenue of €7.59m, a net profit of 215,691 € and equity of €4.61m. With 12.6 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 65.1%, above the median of its sector (46.0%).
Companies similar to Eisai
Companies in the same business, of comparable size and area, outside its group.
- PerkinElmer (Belgium) Wholesale of pharmaceutical and medical goods Kraainem · balance sheet €8.33m
- Hipra Benelux Manufacture of other chemical products n.e.c. Ghent · balance sheet €4.96m
- AIP Medical Manufacture of pharmaceutical preparations Olne · balance sheet €1.64m
- Fortilab Manufacture of pharmaceutical preparations Etterbeek · balance sheet €1.39m
- Belipharm Wholesale of pharmaceutical and medical goods Leuven · balance sheet 449,785 €
- Sanifort Pharma Wholesale of pharmaceutical and medical goods Leuven · balance sheet 408,425 €
- Fagron Belgium Wholesale of pharmaceutical and medical goods Nazareth-De Pinte · balance sheet €7.86m
- Vesale Pharma Woman Health Wholesale of pharmaceutical and medical goods Éghezée · balance sheet 62,158 €
Frequently asked questions about Eisai
What is the revenue of Eisai?
According to the 2026 annual accounts filed with the NBB, the revenue of Eisai amounts to 7,590,065 €.
What is the VAT number of Eisai?
In Belgium, the VAT number is the company number prefixed with BE: BE0891958055 for Eisai, if the company is VAT-registered. Its company number (CBE) is 0891.958.055.
Where is the registered office of Eisai?
According to the CBE register, the registered office of Eisai is in 3000 Leuven.
What is the equity of Eisai?
At the close of the 2026 financial year, the equity of Eisai amounts to 4,610,043 €, a solvency of 65.1% of total assets.
How many people work at Eisai?
12.6 full-time equivalents on average according to the 2026 social balance sheet.
Who manages Eisai?
The register lists 3 active mandates at Eisai. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Eisai
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →